Hazlett, Burt & Watson’s Amicus Therapeutics FOLD Stock Holding History

Hazlett, Burt & Watson’s Portfolio FOLD Stock Details FOLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$23K	Hold	1,569	–	–	0.01%	564
2025 Q4	$22K	Hold	1,569	–	–	0.01%	586
2025 Q3	$12K	Hold	1,569	–	–	﹤0.01%	635
2025 Q2	$9K	Hold	1,569	–	–	﹤0.01%	600
2025 Q1	$13K	Hold	1,569	–	–	0.01%	541
2024 Q4	$15K	Sell	1,569 -1,000	-39%	-$10.4K	0.01%	494
2024 Q3	$28K	Buy	2,569 +1,569	+157%	+$17.1K	0.01%	427
2024 Q2	$10K	Hold	1,000	–	–	0.01%	523
2024 Q1	$12K	Hold	1,000	–	–	0.01%	497
2023 Q4	$14K	Hold	1,000	–	–	0.01%	459
2023 Q3	$12K	Hold	1,000	–	–	0.01%	478
2023 Q2	$13K	Hold	1,000	–	–	0.01%	455
2023 Q1	$11K	Hold	1,000	–	–	0.01%	439
2022 Q4	$12K	Hold	1,000	–	–	0.01%	440
2022 Q3	$10K	Hold	1,000	–	–	0.01%	452
2022 Q2	$11K	Hold	1,000	–	–	0.01%	444
2022 Q1	$9K	Buy	+1,000	New	+$9.38K	0.01%	479

Other funds holding FOLD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

GCL

Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Hazlett, Burt & Watson's FOLD Position: Q1 2026 in Review

Hazlett, Burt & Watson held its Amicus Therapeutics (FOLD) position steady in Q1 2026 at 1,569 shares worth $23K. The position accounts for 0.01% of the portfolio, ranked #564.

Hazlett, Burt & Watson first reported a position in FOLD in Q1 2022 and has held it in 17 quarters since. The position peaked at $28K in Q3 2024. 298 funds tracked by Wall St. Rank hold FOLD as of Q1 2026.

Hazlett, Burt & Watson held 1,569 shares of Amicus Therapeutics worth $23K as of Q1 2026.
Hazlett, Burt & Watson left its Amicus Therapeutics share count unchanged in Q1 2026.
Amicus Therapeutics made up 0.01% of Hazlett, Burt & Watson's portfolio in Q1 2026, its #564 holding.
Hazlett, Burt & Watson first reported a position in Amicus Therapeutics in Q1 2022 and has held it in 17 quarters since.
Hazlett, Burt & Watson's Amicus Therapeutics position peaked at $28K in Q3 2024.
298 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q1 2026.

Based on Hazlett, Burt & Watson's 13F filing for Q1 2026, filed 14 May 2026.